红肿
发表于 2025-3-23 09:51:59
http://reply.papertrans.cn/19/1886/188568/188568_11.png
先驱
发表于 2025-3-23 16:11:06
http://reply.papertrans.cn/19/1886/188568/188568_12.png
绝食
发表于 2025-3-23 19:57:41
The Changing US Reimbursement Landscape and Biosimilarse passage of the Affordable Care Act (ACA) created an FDA approval pathway for biosimilars, but that is the tip of the iceberg as it pertains to how a biosimilar will actually get to the patient. As a general rule, legislation contains very little detail and requires much regulatory guidance by vari
新星
发表于 2025-3-23 23:55:31
http://reply.papertrans.cn/19/1886/188568/188568_14.png
冷峻
发表于 2025-3-24 05:07:56
Design and Implementation of Successful Regulatory Strategies in Biosimilar Developmenten shown to provide “dramatically reduced disability for patients with inflammatory diseases, such as rheumatoid arthritis, extended the lives of patients with many cancers and also provide lifesaving replacement proteins for patients with rare diseases” (US Food and Drug Administration, .; Krishnan
Adrenaline
发表于 2025-3-24 06:35:04
http://reply.papertrans.cn/19/1886/188568/188568_16.png
夸张
发表于 2025-3-24 13:09:40
EU Perspective on Biosimilarsation is granted by the Commission of the European Union (EU). Thus, each biosimilar has one regulatory assessment as well as the same product information and conditions of use in the EU. The current regulatory framework is a result of 20 years evolution of legislation and regulatory guidelines. The
怒目而视
发表于 2025-3-24 18:04:08
http://reply.papertrans.cn/19/1886/188568/188568_18.png
协定
发表于 2025-3-24 22:45:37
QbD in Biopharmaceutical Manufacturing and Biosimilar Developments had been proven, clinical efficacy and safety profiles established, with large markets and sales margins, making them attractive targets for many biopharmaceutical companies, both large and small. However, inherent properties of the molecules result in higher levels of risk in the eyes of regulato
condemn
发表于 2025-3-24 23:59:45
Drug Product Considerations for Biosimilarsn of the drug product for a biosimilar is of utmost importance, as it directly relates to patient efficacy, safety and product quality, even as it defines the similarity of the product to the reference innovator product. There are various components of a drug product: the formulation, the container